A Phase 1 interventional study of Orforglipron in Healthy, Obese and Overweight, sponsored by Eli Lilly and Company. Completed at 7 sites in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-17.
Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies testing orforglipron in Obesity — 4 open to participants now, 10 under way, 9 of them phase 3. orforglipron · Obesity.
Among the 22 studies testing orforglipron in Obesity, this one is the 9th largest by enrollment, is one of 6 that started in 2024, is one of 6 in phase 1, and was the 10th registered.
11,543 studies on the registry are indexed under Obesity; 2,042 are open to participants now.
Browse Obesity studies →4 of the 22 studies testing orforglipron in Obesity are open now, in 12 countries. Recruiting first, the newest first:
Eli Lilly and Company · Sites in United States, Belgium, Brazil and 10 more countries
Ages 6–17
Eli Lilly and Company · Sites in United States, Israel, Italy and 3 more countries
Ages 12–17
Eli Lilly and Company · Sites in China
Ages 18+
Massachusetts General Hospital · Sites in United States
Ages 18–80
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 1,339 Obesity studies recruiting now, 377 (28%) set no upper age limit and 859 (64%) stop at 75 or younger; 167 take children under 18; 490 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, orforglipron is the treatment under test here. Read study by study →
22 studies; the count open now beside each. This study's row is marked.
First in 2021; this study’s year is marked. 6 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 533 is above the median of 67 across 9,016 interventional studies indexed under Obesity.
Median enrollment 324 across the 22 interventional studies. Of the 12 that completed or were terminated, 8 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
21 of 22 have an industry lead sponsor. The 2 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
118 studies in Obesity by Eli Lilly and Company: 31 open now, 55 under way, 30 of them phase 3. Of 61 finished, 29 (48%) have results posted.
Among the 118 studies in Obesity by Eli Lilly and Company, this one is the 35th largest by enrollment of the 117 interventional ones that give a count, is one of 20 that started in 2024, is one of 40 in phase 1, and was the 52nd registered.
Eli Lilly and Company’s Obesity studies by the year they started, since 2009.
5 of the studies testing orforglipron in Obesity that are under way reach primary completion within a year, 5 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06672549Phase 3Eli Lilly and CompanyA Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040) | 2027-02 |
| NCT06993792Phase 3Eli Lilly and CompanyA Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes | 2027-08 |
| NCT06972459Phase 3Eli Lilly and CompanyA Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity | 2027-08 |
| NCT06972472Phase 3Eli Lilly and CompanyA Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes | 2027-08 |
| NCT06948435Phase 3Eli Lilly and CompanyA Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1 | 2027-09 |
Add all 5 to your calendar (.ics) → With an account.
Among the 22 studies testing orforglipron in Obesity, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Eli Lilly and Company’s 118 in Obesity:
This tab as a report to print or save as PDF → With an account.
The main purpose of this study is to see how much of orforglipron (study drug) gets into the bloodstream and how long it takes the body to get rid of it when given as capsules compared to tablets in healthy overweight and obese participants. The safety and tolerability (side effects) of orforglipron when given as capsules and tablets will also be evaluated.
The study will be conducted in two parts, with part A and B lasting up to approximately 25 and 22 weeks each respectively, including the screening period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received LY3502970 orally once daily (QD) across inpatient Treatment Periods 1-12 (7 days per period), followed by a follow-up visit approximately 7 days after the last dose. Doses were administered as follows: * Period 1: 1 mg (Capsule) * Period 2: Dose Level 2 (Tablet) * Period 3: Dose Level 1 (Tablet) * Period 4: Dose Level 3 (Tablet) * Period 5: 3 mg (Capsule) * Period 6: Dose Level 5 (Tablet) * Period 7: Dose Level 4 (Tablet) * Period 8: Dose Level 6 (Tablet) * Period 9: 6 mg (Capsule) * Period 10: Dose Level 8 (Tablet) * Period 11: Dose Level 7 (Tablet) * Period 12: Dose Level 9 (Tablet)
Drug: Orforglipron
Participants received LY3502970 orally QD across inpatient Treatment Periods 1-12 (7 days per period), followed by a follow-up visit approximately 7 days after the last dose. Doses were administered as follows: * Period 1: Dose Level 2 (Tablet) * Period 2: 1 mg (Capsule) * Period 3: Dose Level 3 (Tablet) * Period 4: Dose Level 1 (Tablet) * Period 5: Dose Level 5 (Tablet) * Period 6: 3 mg (Capsule) * Period 7: Dose Level 6 (Tablet) * Period 8: Dose Level 4 (Tablet) * Period 9: Dose Level 8 (Tablet) * Period 10: 6 mg (Capsule) * Period 11: Dose Level 9 (Tablet) * Period 12: Dose Level 7 (Tablet)
Drug: Orforglipron
Participants received LY3502970 orally QD across inpatient Treatment Periods 1-12 (7 days per period), followed by a follow-up visit approximately 7 days after the last dose. Doses were administered as follows: * Period 1: Dose Level 1 (Tablet) * Period 2: Dose Level 3 (Tablet) * Period 3: 1 mg (Capsule) * Period 4: Dose Level 2 (Tablet) * Period 5: Dose Level 4 (Tablet) * Period 6: Dose Level 6 (Tablet) * Period 7: 3 mg (Capsule) * Period 8: Dose Level 5 (Tablet) * Period 9: Dose Level 7 (Tablet) * Period 10: Dose Level 9 (Tablet) * Period 11: 6 mg (Capsule) * Period 12: Dose Level 8 (Tablet)
Drug: Orforglipron
Participants received LY3502970 orally QD across inpatient Treatment Periods 1-12 (7 days per period), followed by a follow-up visit approximately 7 days after the last dose. Doses were administered as follows: * Period 1: Dose Level 3 (Tablet) * Period 2: Dose Level 1 (Tablet) * Period 3: Dose Level 2 (Tablet) * Period 4: 1 mg (Capsule) * Period 5: Dose Level 6 (Tablet) * Period 6: Dose Level 4 (Tablet) * Period 7: Dose Level 5 (Tablet) * Period 8: 3 mg (Capsule) * Period 9: Dose Level 9 (Tablet) * Period 10: Dose Level 7 (Tablet) * Period 11: Dose Level 8 (Tablet) * Period 12: 6 mg (Capsule)
Drug: Orforglipron
Participants received LY3502970 orally QD during home dosing Treatment Periods 1-6 (1 mg, 3 mg and 6 mg; Capsule), followed by inpatient Treatment Periods 7-18 (7 days per period) and a follow-up visit approximately 7 days after the last dose. Doses during inpatient periods were administered as follows: * Period 7: 12 mg (Capsule) * Period 8: Dose Level 11 (Tablet) * Period 9: Dose Level 10 (Tablet) * Period 10: Dose Level 12 (Tablet) * Period 11: 24 mg (Capsule) * Period 12: Dose Level 14 (Tablet) * Period 13: Dose Level 13 (Tablet) * Period 14: Dose Level 16 (Tablet) * Period 15: 36 mg (Capsule) * Period 16: Dose Level 17 (Tablet) * Period 17: Dose Level 15 (Tablet) * Period 18: Dose Level 18 (Tablet)
Drug: Orforglipron
Participants received LY3502970 orally QD during home dosing Treatment Periods 1-6 (1 mg, 3 mg, and 6 mg; Capsule), followed by inpatient Treatment Periods 7-18 (7 days per period) and a follow-up visit approximately 7 days after the last dose. Doses during inpatient periods were administered as follows: * Period 7: Dose Level 11 (Tablet) * Period 8: 12 mg (Capsule) * Period 9: Dose Level 12 (Tablet) * Period 10: Dose Level 10 (Tablet) * Period 11: Dose Level 14 (Tablet) * Period 12: 24 mg (Capsule) * Period 13: Dose Level 16 (Tablet) * Period 14: Dose Level 13 (Tablet) * Period 15: Dose Level 17 (Tablet) * Period 16: 36 mg (Capsule) * Period 17: Dose Level 18 (Tablet) * Period 18: Dose Level 15 (Tablet)
Drug: Orforglipron
Participants received LY3502970 orally QD during home dosing Treatment Periods 1-6 (1 mg, 3 mg and 6 mg; Capsule), followed by inpatient Treatment Periods 7-18 (7 days per period) and a follow-up visit approximately 7 days after the last dose. Doses during inpatient periods were administered as follows: * Period 7: Dose Level 10 (Tablet) * Period 8: Dose Level 12 (Tablet) * Period 9: 12 mg (Capsule) * Period 10: Dose Level 11 (Tablet) * Period 11: Dose Level 13 (Tablet) * Period 12: Dose Level 16 (Tablet) * Period 13: 24 mg (Capsule) * Period 14: Dose Level 14 (Tablet) * Period 15: Dose Level 15 (Tablet) * Period 16: Dose Level 18 (Tablet) * Period 17: 36 mg (Capsule) * Period 18: Dose Level 17 (Tablet)
Drug: Orforglipron
Participants received LY3502970 orally QD during home dosing Treatment Periods 1-6 (1 mg, 3 mg, and 6 mg; Capsule), followed by inpatient Treatment Periods 7-18 (7 days per period) and a follow-up visit approximately 7 days after the last dose. Doses during inpatient periods were administered as follows: * Period 7: Dose Level 12 (Tablet) * Period 8: Dose Level 10 (Tablet) * Period 9: Dose Level 11 (Tablet) * Period 10: 12 mg (Capsule) * Period 11: Dose Level 16 (Tablet) * Period 12: Dose Level 13 (Tablet) * Period 13: Dose Level 14 (Tablet) * Period 14: 24 mg (Capsule) * Period 15: Dose Level 18 (Tablet) * Period 16: Dose Level 15 (Tablet) * Period 17: Dose Level 17 (Tablet) * Period 18: 36 mg (Capsule)
Drug: Orforglipron
Participants received LY3502970 orally QD across inpatient Treatment Periods 1-9 (7 days per period), followed by a follow-up visit approximately 7 days after the last dose. Doses were administered as follows: * Period 1: 1 mg (Capsule- First Treatment) * Period 2: 1 mg (Capsule- Second Treatment) * Period 3: 0.8 mg (Tablet) * Period 4: 3 mg (Capsule- First Treatment) * Period 5: 3 mg (Capsule- Second Treatment) * Period 6: 2.5 mg (Tablet) * Period 7: 6 mg (Capsule- First Treatment) * Period 8: 6 mg (Capsule- Second Treatment) * Period 9: 5.5 mg (Tablet)
Drug: Orforglipron
Participants received LY3502970 orally QD across inpatient Treatment Periods 1-9 (7 days per period), followed by a follow-up visit approximately 7 days after the last dose. Doses were administered as follows: * Period 1: 1 mg (Capsule- First Treatment) * Period 2: 0.8 mg (Tablet) * Period 3: 1 mg (Capsule- Second Treatment) * Period 4: 3 mg (Capsule- First Treatment) * Period 5: 2.5 mg (Tablet) * Period 6: 3 mg (Capsule- Second Treatment) * Period 7: 6 mg (Capsule- First Treatment) * Period 8: 5.5 mg (Tablet) * Period 9: 6 mg (Capsule- Second Treatment)
Drug: Orforglipron
Participants received LY3502970 orally QD across inpatient Treatment Periods 1-9 (7 days per period), followed by a follow-up visit approximately 7 days after the last dose. Doses were administered as follows: * Period 1: 0.8 mg (Tablet) * Period 2: 1 mg (Capsule- First Treatment) * Period 3: 1 mg (Capsule- Second Treatment) * Period 4: 2.5 mg (Tablet) * Period 5: 3 mg (Capsule- First Treatment) * Period 6: 3 mg (Capsule- Second Treatment) * Period 7: 5.5 mg (Tablet) * Period 8: 6 mg (Capsule- First Treatment) * Period 9: 6 mg (Capsule- Second Treatment)
Drug: Orforglipron
Participants received LY3502970 orally QD during home dosing Treatment Periods 1-6 (1 mg, 3 mg, and 6 mg \[Capsule\]), followed by inpatient Treatment Periods 7-15 (7 days per period) and a follow-up visit approximately 7 days after the last dose. Doses during inpatient periods were administered as follows: * Period 7: 12 mg (Capsule- First Treatment) * Period 8: 12 mg (Capsule- Second Treatment) * Period 9: 9 mg (Tablet) * Period 10: 24 mg (Capsule- First Treatment) * Period 11: 24 mg (Capsule- Second Treatment) * Period 12: 14.5 mg (Tablet) * Period 13: 36 mg (Capsule- First Treatment) * Period 14: 36 mg (Capsule- Second Treatment) * Period 15: 17.2 mg (Tablet)
Drug: Orforglipron
Participants received LY3502970 orally QD during home dosing Treatment Periods 1-6 (1 mg, 3 mg, and 6 mg \[Capsule\]), followed by inpatient Treatment Periods 7-15 (7 days per period) and a follow-up visit approximately 7 days after the last dose. Doses during inpatient periods were administered as follows: * Period 7: 12 mg (Capsule- First Treatment) * Period 8: 9 mg (Tablet) * Period 9: 12 mg (Capsule- Second Treatment) * Period 10: 24 mg (Capsule- First Treatment) * Period 11: 14.5 mg (Tablet) * Period 12: 24 mg (Capsule- Second Treatment) * Period 13: 36 mg (Capsule- First Treatment) * Period 14: 17.2 mg (Tablet) * Period 15: 36 mg (Capsule- Second Treatment)
Drug: Orforglipron
Participants received LY3502970 orally QD during home dosing Treatment Periods 1-6 (1 mg, 3 mg, and 6 mg \[Capsule\]), followed by inpatient Treatment Periods 7-15 (7 days per period) and a follow-up visit approximately 7 days after the last dose. Doses during inpatient periods were administered as follows: * Period 7: 9 mg (Tablet) * Period 8: 12 mg (Capsule- First Treatment) * Period 9: 12 mg (Capsule- Second Treatment) * Period 10: 14.5 mg (Tablet) * Period 11: 24 mg (Capsule- First Treatment) * Period 12: 24 mg (Capsule- Second Treatment) * Period 13: 17.2 mg (Tablet) * Period 14: 36 mg (Capsule- First Treatment) * Period 15: 36 mg (Capsule- Second Treatment)
Drug: Orforglipron
Administered orally
Also known as: LY3502970
Part B: Pharmacokinetics (PK): Steady-state Area Under the Concentration Time Curve From Time Zero to the End of the Dosing Interval, Tau (AUC[0-tau]) of LY3502970 on Day 7
PK: Area under the concentration versus time curve from time 0 to the end of the once daily dosing interval at steady state AUC\[0-tau\] on Day 7.
Time frame: Pre-dose, 0.5, 1, 2, 4, 6, 8, 12, 16 and 24 hours post-dose on Day 7 for each dosing treatment period (1 period=7 days)
Part B: PK: Steady-state Maximum Observed Concentration (Cmax) of LY3502970 on Day 7
PK: Maximum concentration of LY3502970 during a once daily dosing interval at steady state on Day 7.
Time frame: Pre-dose, 0.5, 1, 2, 4, 6, 8, 12, 16 and 24 hours post-dose on Day 7 for each dosing treatment period (1 period=7 days)
This study enrolled 533 participants across 4 mutually exclusive cohorts in 2 parts: Part A (pilot relative bioavailability; Cohorts 1A and 2A) and Part B (bioequivalence; Cohorts 1B and 2B). As per sponsor decision, for Part A tablet (Cohorts 1A and 2A), dose levels are presented as Dose Level 1 through Dose Level 18, where Dose Level 1 represents the lowest dose and Dose Level 18 represents the highest dose.
| Milestone | Part A: LY3502970 QD Oral Administration (Cohort 1A, Sequence 1) | Part A: LY3502970 Oral Administration (Cohort 1A, Sequence 2) | Part A: LY3502970 Oral Administration (Cohort 1A, Sequence 3) | Part A: LY3502970 Oral Administration (Cohort 1A, Sequence 4) | Part A: LY3502970 Oral Administration (Cohort 2A, Sequence 1) | Part A: LY3502970 Oral Administration (Cohort 2A, Sequence 2) | Part A: LY3502970 Oral Administration (Cohort 2A, Sequence 3) | Part A: LY3502970 Oral Administration (Cohort 2A, Sequence 4) | Part B: LY3502970 Oral Administration (Cohort 1B, Sequence 1) | Part B: LY3502970 Oral Administration (Cohort 1B, Sequence 2) | Part B: LY3502970 Oral Administration (Cohort 1B, Sequence 3) | Part B: LY3502970 Oral Administration (Cohort 2B, Sequence 1) | Part B: LY3502970 Oral Administration (Cohort 2B, Sequence 2) | Part B: LY3502970 Oral Administration (Cohort 2B, Sequence 3) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 13 | 13 | 13 | 13 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Period 1 | 13 | 13 | 13 | 13 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Period 2 | 13 | 13 | 13 | 13 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Period 3 | 13 | 13 | 13 | 13 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Period 4 | 13 | 13 | 13 | 13 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Period 5 | 13 | 13 | 12 | 13 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Period 6 | 13 | 13 | 12 | 13 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Period 7 | 13 | 13 | 10 | 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Period 8 | 13 | 13 | 10 | 11 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Period 9 | 13 | 13 | 10 | 11 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Period 10 | 13 | 12 | 10 | 11 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Period 11 | 13 | 12 | 10 | 11 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Period 12 | 13 | 12 | 10 | 11 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 13 | 12 | 10 | 10 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 1 | 3 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 0 | 3 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Physician decision | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Part A: LY3502970 QD Oral Administration (Cohort 1A, Sequence 1) | Part A: LY3502970 Oral Administration (Cohort 1A, Sequence 2) | Part A: LY3502970 Oral Administration (Cohort 1A, Sequence 3) | Part A: LY3502970 Oral Administration (Cohort 1A, Sequence 4) | Part A: LY3502970 Oral Administration (Cohort 2A, Sequence 1) | Part A: LY3502970 Oral Administration (Cohort 2A, Sequence 2) | Part A: LY3502970 Oral Administration (Cohort 2A, Sequence 3) | Part A: LY3502970 Oral Administration (Cohort 2A, Sequence 4) | Part B: LY3502970 Oral Administration (Cohort 1B, Sequence 1) | Part B: LY3502970 Oral Administration (Cohort 1B, Sequence 2) | Part B: LY3502970 Oral Administration (Cohort 1B, Sequence 3) | Part B: LY3502970 Oral Administration (Cohort 2B, Sequence 1) | Part B: LY3502970 Oral Administration (Cohort 2B, Sequence 2) | Part B: LY3502970 Oral Administration (Cohort 2B, Sequence 3) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 15 | 12 | 13 | 12 | 0 | 0 | 0 | 0 | 0 | 0 |
| Home-dosing (period 1-6) | 0 | 0 | 0 | 0 | 15 | 12 | 13 | 12 | 0 | 0 | 0 | 0 | 0 | 0 |
| Period 7 | 0 | 0 | 0 | 0 | 13 | 12 | 13 | 12 | 0 | 0 | 0 | 0 | 0 | 0 |
| Period 8 | 0 | 0 | 0 | 0 | 13 | 12 | 13 | 12 | 0 | 0 | 0 | 0 | 0 | 0 |
| Period 9 | 0 | 0 | 0 | 0 | 13 | 12 | 13 | 12 | 0 | 0 | 0 | 0 | 0 | 0 |
| Period 10 | 0 | 0 | 0 | 0 | 13 | 12 | 13 | 12 | 0 | 0 | 0 | 0 | 0 | 0 |
| Period 11 | 0 | 0 | 0 | 0 | 13 | 12 | 13 | 12 | 0 | 0 | 0 | 0 | 0 | 0 |
| Period 12 | 0 | 0 | 0 | 0 | 13 | 12 | 13 | 12 | 0 | 0 | 0 | 0 | 0 | 0 |
| Period 13 | 0 | 0 | 0 | 0 | 13 | 12 | 13 | 12 | 0 | 0 | 0 | 0 | 0 | 0 |
| Period 14 | 0 | 0 | 0 | 0 | 13 | 11 | 12 | 12 | 0 | 0 | 0 | 0 | 0 | 0 |
| Period 15 | 0 | 0 | 0 | 0 | 11 | 10 | 12 | 12 | 0 | 0 | 0 | 0 | 0 | 0 |
| Period 16 | 0 | 0 | 0 | 0 | 11 | 10 | 12 | 12 | 0 | 0 | 0 | 0 | 0 | 0 |
| Period 17 | 0 | 0 | 0 | 0 | 11 | 10 | 12 | 12 | 0 | 0 | 0 | 0 | 0 | 0 |
| Period 18 | 0 | 0 | 0 | 0 | 11 | 10 | 12 | 12 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 | 11 | 10 | 12 | 12 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 4 | 2 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Physician decision | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Part A: LY3502970 QD Oral Administration (Cohort 1A, Sequence 1) | Part A: LY3502970 Oral Administration (Cohort 1A, Sequence 2) | Part A: LY3502970 Oral Administration (Cohort 1A, Sequence 3) | Part A: LY3502970 Oral Administration (Cohort 1A, Sequence 4) | Part A: LY3502970 Oral Administration (Cohort 2A, Sequence 1) | Part A: LY3502970 Oral Administration (Cohort 2A, Sequence 2) | Part A: LY3502970 Oral Administration (Cohort 2A, Sequence 3) | Part A: LY3502970 Oral Administration (Cohort 2A, Sequence 4) | Part B: LY3502970 Oral Administration (Cohort 1B, Sequence 1) | Part B: LY3502970 Oral Administration (Cohort 1B, Sequence 2) | Part B: LY3502970 Oral Administration (Cohort 1B, Sequence 3) | Part B: LY3502970 Oral Administration (Cohort 2B, Sequence 1) | Part B: LY3502970 Oral Administration (Cohort 2B, Sequence 2) | Part B: LY3502970 Oral Administration (Cohort 2B, Sequence 3) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 72 | 72 | 72 | 0 | 0 | 0 |
| Period 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 72 | 72 | 72 | 0 | 0 | 0 |
| Period 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 71 | 70 | 71 | 0 | 0 | 0 |
| Period 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 71 | 69 | 71 | 0 | 0 | 0 |
| Period 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 71 | 69 | 71 | 0 | 0 | 0 |
| Period 5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 71 | 68 | 70 | 0 | 0 | 0 |
| Period 6 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 71 | 67 | 69 | 0 | 0 | 0 |
| Period 7 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 70 | 67 | 68 | 0 | 0 | 0 |
| Period 8 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 69 | 66 | 66 | 0 | 0 | 0 |
| Period 9 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 69 | 65 | 66 | 0 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 69 | 64 | 66 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 8 | 6 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 2 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 1 | 2 | 0 | 0 | 0 |
| Withdrew: Physician decision | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 5 | 2 | 0 | 0 | 0 |
| Milestone | Part A: LY3502970 QD Oral Administration (Cohort 1A, Sequence 1) | Part A: LY3502970 Oral Administration (Cohort 1A, Sequence 2) | Part A: LY3502970 Oral Administration (Cohort 1A, Sequence 3) | Part A: LY3502970 Oral Administration (Cohort 1A, Sequence 4) | Part A: LY3502970 Oral Administration (Cohort 2A, Sequence 1) | Part A: LY3502970 Oral Administration (Cohort 2A, Sequence 2) | Part A: LY3502970 Oral Administration (Cohort 2A, Sequence 3) | Part A: LY3502970 Oral Administration (Cohort 2A, Sequence 4) | Part B: LY3502970 Oral Administration (Cohort 1B, Sequence 1) | Part B: LY3502970 Oral Administration (Cohort 1B, Sequence 2) | Part B: LY3502970 Oral Administration (Cohort 1B, Sequence 3) | Part B: LY3502970 Oral Administration (Cohort 2B, Sequence 1) | Part B: LY3502970 Oral Administration (Cohort 2B, Sequence 2) | Part B: LY3502970 Oral Administration (Cohort 2B, Sequence 3) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 87 | 63 | 63 |
| Period 1-6 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 87 | 63 | 63 |
| Period 7 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 63 | 62 | 63 |
| Period 8 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 62 | 61 | 61 |
| Period 9 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 62 | 61 | 59 |
| Period 10 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 61 | 61 | 59 |
| Period 11 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 60 | 61 | 59 |
| Period 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 60 | 61 | 58 |
| Period 13 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 59 | 60 | 58 |
| Period 14 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 58 | 60 | 57 |
| Period 15 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 58 | 60 | 57 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 58 | 60 | 56 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 29 | 3 | 7 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 9 | 1 | 4 |
| Withdrew: Physician decision | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 6 | 1 | 1 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 8 | 1 | 2 |
| Withdrew: Non-compliance with study drug | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Screen failure | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 |
| Withdrew: Protocol deviation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 0 | 0 |
PK: Area under the concentration versus time curve from time 0 to the end of the once daily dosing interval at steady state AUC\[0-tau\] on Day 7.
| Nanogram* hours/milliliter (ng*h/ml) | Cohort 1B: 1 mg LY3502970 Capsule QD (First Treatment) | Cohort 1B: 1 mg LY3502970 Capsule QD (Second Treatment) | Cohort 1B: 0.8 mg LY3502970 Tablet QD | Cohort 1B: 3 mg LY3502970 Capsule QD (First Treatment) | Cohort 1B: 3 mg LY3502970 Capsule QD (Second Treatment) | Cohort 1B: 2.5 mg LY3502970 Tablet QD | Cohort 1B: 6 mg LY3502970 Capsule QD (First Treatment) | Cohort 1B: 6 mg LY3502970 Capsule QD (Second Treatment) | Cohort 1B: 5.5 mg LY3502970 Tablet QD | Cohort 2B: 12 mg LY3502970 Capsule QD (First Treatment) | Cohort 2B: 12 mg LY3502970 Capsule QD (Second Treatment) | Cohort 2B: 9 mg LY3502970 Tablet QD | Cohort 2B: 24 mg LY3502970 Capsule QD (First Treatment) | Cohort 2B: 24 mg LY3502970 Capsule QD (Second Treatment) | Cohort 2B: 14.5 mg LY3502970 Tablet QD | Cohort 2B: 36 mg LY3502970 Capsule QD (First Treatment) | Cohort 2B: 36 mg LY3502970 Capsule QD (Second Treatment) | Cohort 2B: 17.2 mg LY3502970 Tablet QD |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Part B: Pharmacokinetics (PK): Steady-state Area Under the Concentration Time Curve From Time Zero to the End of the Dosing Interval, Tau (AUC[0-tau]) of LY3502970 on Day 7 | 80.2 ± 37.8 | 82.1 ± 39.7 | 78.9 ± 36.6 | 240 ± 38.8 | 252 ± 39.1 | 247 ± 37.3 | 517 ± 47.4 | 541 ± 60.4 | 524 ± 45.4 | 829 ± 46.4 | 841 ± 46.3 | 790 ± 40.3 | 1210 ± 50.0 | 1260 ± 57.5 | 1200 ± 64.2 | 1500 ± 71.5 | 1500 ± 71.9 | 1520 ± 60.4 |
PK: Maximum concentration of LY3502970 during a once daily dosing interval at steady state on Day 7.
| Nanogram per milliliter (ng/ml) | Cohort 1B: 1 mg LY3502970 Capsule QD (First Treatment) | Cohort 1B: 1 mg LY3502970 Capsule QD (Second Treatment) | Cohort 1B: 0.8 mg LY3502970 Tablet QD | Cohort 1B: 3 mg LY3502970 Capsule QD (First Treatment) | Cohort 1B: 3 mg LY3502970 Capsule QD (Second Treatment) | Cohort 1B: 2.5 mg LY3502970 Tablet QD | Cohort 1B: 6 mg LY3502970 Capsule QD (First Treatment) | Cohort 1B: 6 mg LY3502970 Capsule QD (Second Treatment) | Cohort 1B: 5.5 mg LY3502970 Tablet QD | Cohort 2B: 12 mg LY3502970 Capsule QD (First Treatment) | Cohort 2B: 12 mg LY3502970 Capsule QD (Second Treatment) | Cohort 2B: 9 mg LY3502970 Tablet QD | Cohort 2B: 24 mg LY3502970 Capsule QD (First Treatment) | Cohort 2B: 24 mg LY3502970 Capsule QD (Second Treatment) | Cohort 2B: 14.5 mg LY3502970 Tablet QD | Cohort 2B: 36 mg LY3502970 Capsule QD (First Treatment) | Cohort 2B: 36 mg LY3502970 Capsule QD (Second Treatment) | Cohort 2B: 17.2 mg LY3502970 Tablet QD |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Part B: PK: Steady-state Maximum Observed Concentration (Cmax) of LY3502970 on Day 7 | 5.39 ± 37.9 | 5.60 ± 39.5 | 5.38 ± 35.9 | 16.2 ± 41.2 | 16.8 ± 38.8 | 16.8 ± 37.4 | 35.1 ± 50.0 | 36.8 ± 63.6 | 34.9 ± 63.9 | 55.0 ± 55.0 | 55.6 ± 51.3 | 53.5 ± 41.7 | 80.0 ± 52.1 | 82.6 ± 60.6 | 82.2 ± 67.7 | 96.9 ± 74.4 | 96.2 ± 75.8 | 105 ± 65.2 |
Collected over Cohort 1A: Baseline Up to end of follow up (Up to 13 weeks); Cohort 2A: Baseline Up to end of follow up (Up to 19 weeks); Cohort 1B: Baseline Up to end of follow up (Up to 10 weeks); Cohort 2B: Baseline Up to end of follow up (Up to 16 weeks).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort 1A: 1 mg LY3502970 Capsule QD | 0/52 (0%) | 0/52 (0%) | 6/52 (11.5%) |
| Cohort 1A: LY3502970 Tablet QD (Dose Level 1) | 0/52 (0%) | 0/52 (0%) | 8/52 (15.4%) |
| Cohort 1A: LY3502970 Tablet QD (Dose Level 2) | 0/52 (0%) | 0/52 (0%) | 7/52 (13.5%) |
| Cohort 1A: LY3502970 Tablet QD (Dose Level 3) | 0/52 (0%) | 0/52 (0%) | 9/52 (17.3%) |
| Cohort 1A: 3 mg LY3502970 Capsule QD | 0/47 (0%) | 0/47 (0%) | 6/47 (12.8%) |
| Cohort 1A: LY3502970 Tablet QD (Dose Level 4) | 0/51 (0%) | 0/51 (0%) | 9/51 (17.6%) |
| Cohort 1A: LY3502970 Tablet QD (Dose Level 5) | 0/48 (0%) | 0/48 (0%) | 10/48 (20.8%) |
| Cohort 1A: LY3502970 Tablet QD (Dose Level 6) | 0/51 (0%) | 0/51 (0%) | 13/51 (25.5%) |
| Cohort 1A: 6 mg LY3502970 Capsule QD | 0/46 (0%) | 0/46 (0%) | 7/46 (15.2%) |
| Cohort 1A: LY3502970 Tablet QD (Dose Level 7) | 0/46 (0%) | 0/46 (0%) | 6/46 (13%) |
| Cohort 1A: LY3502970 Tablet QD (Dose Level 8) | 0/47 (0%) | 0/47 (0%) | 7/47 (14.9%) |
| Cohort 1A: LY3502970 Tablet QD (Dose Level 9) | 0/46 (0%) | 0/46 (0%) | 10/46 (21.7%) |
| Cohort 2A: 1/3/6 mg LY3502970 Capsule QD (Home Dosing) | 0/52 (0%) | 0/52 (0%) | 11/52 (21.2%) |
| Cohort 2A: 12 mg LY3502970 Capsule QD | 0/50 (0%) | 0/50 (0%) | 7/50 (14%) |
| Cohort 2A: LY3502970 Tablet QD (Dose Level 10) | 0/50 (0%) | 0/50 (0%) | 16/50 (32%) |
| Cohort 2A:LY3502970 Tablet QD (Dose Level 11) | 0/50 (0%) | 0/50 (0%) | 11/50 (22%) |
| Cohort 2A: LY3502970 Tablet QD (Dose Level 12) | 0/50 (0%) | 0/50 (0%) | 8/50 (16%) |
| Cohort 2A: 24 mg LY3502970 Capsule QD | 0/50 (0%) | 0/50 (0%) | 13/50 (26%) |
| Cohort 2A: LY3502970 Tablet QD (Dose Level 13) | 0/49 (0%) | 1/49 (2%) | 10/49 (20.4%) |
| Cohort 2A: LY3502970 Tablet QD (Dose Level 14) | 0/49 (0%) | 0/49 (0%) | 13/49 (26.5%) |
| Cohort 2A: LY3502970 Tablet QD (Dose Level 15) | 0/50 (0%) | 0/50 (0%) | 10/50 (20%) |
| Cohort 2A: 36 mg LY3502970 Capsule QD | 0/45 (0%) | 0/45 (0%) | 9/45 (20%) |
| Cohort 2A: LY3502970 Tablet QD (Dose Level 16) | 0/45 (0%) | 0/45 (0%) | 9/45 (20%) |
| Cohort 2A:LY3502970 Tablet QD (Dose Level 17) | 0/45 (0%) | 0/45 (0%) | 9/45 (20%) |
| Cohort 2A: LY3502970 Tablet QD (Dose Level 18) | 0/45 (0%) | 0/45 (0%) | 9/45 (20%) |
| Cohort 1B: 1 mg LY3502970 Capsule QD | 0/215 (0%) | 0/215 (0%) | 92/215 (42.8%) |
| Cohort 1B: 0.8 mg LY3502970 Tablet QD | 0/213 (0%) | 0/213 (0%) | 49/213 (23%) |
| Cohort 1B: 3 mg LY3502970 Capsule QD | 0/210 (0%) | 0/210 (0%) | 96/210 (45.7%) |
| Cohort 1B: 2.5 mg LY3502970 Tablet QD | 0/210 (0%) | 0/210 (0%) | 57/210 (27.1%) |
| Cohort 1B: 6 mg LY3502970 Capsule QD | 0/203 (0%) | 1/203 (0.5%) | 80/203 (39.4%) |
| Cohort 1B:5.5 mg LY3502970 Tablet QD | 0/203 (0%) | 1/203 (0.5%) | 51/203 (25.1%) |
| Cohort 2B:1/3/6 mg LY3502970 Capsule QD (Home Dosing) | 0/213 (0%) | 0/213 (0%) | 111/213 (52.1%) |
| Cohort 2B:12 mg LY3502970 Capsule QD | 0/186 (0%) | 0/186 (0%) | 97/186 (52.2%) |
| Cohort 2B:9 mg LY3502970 Tablet QD | 0/186 (0%) | 0/186 (0%) | 61/186 (32.8%) |
| Cohort 2B:24 mg LY3502970 Capsule QD | 0/181 (0%) | 0/181 (0%) | 85/181 (47%) |
| Cohort 2B:14.5 mg LY3502970 Tablet QD | 0/180 (0%) | 0/180 (0%) | 56/180 (31.1%) |
| Cohort 2B: 36 mg LY3502970 Capsule QD | 0/176 (0%) | 1/176 (0.6%) | 66/176 (37.5%) |
| Cohort 2B: 17.2 mg LY3502970 Tablet QD | 0/176 (0%) | 0/176 (0%) | 35/176 (19.9%) |
| Event | Cohort 1A: 1 mg LY3502970 Capsule QD | Cohort 1A: LY3502970 Tablet QD (Dose Level 1) | Cohort 1A: LY3502970 Tablet QD (Dose Level 2) | Cohort 1A: LY3502970 Tablet QD (Dose Level 3) | Cohort 1A: 3 mg LY3502970 Capsule QD | Cohort 1A: LY3502970 Tablet QD (Dose Level 4) | Cohort 1A: LY3502970 Tablet QD (Dose Level 5) | Cohort 1A: LY3502970 Tablet QD (Dose Level 6) | Cohort 1A: 6 mg LY3502970 Capsule QD | Cohort 1A: LY3502970 Tablet QD (Dose Level 7) | Cohort 1A: LY3502970 Tablet QD (Dose Level 8) | Cohort 1A: LY3502970 Tablet QD (Dose Level 9) | Cohort 2A: 1/3/6 mg LY3502970 Capsule QD (Home Dosing) | Cohort 2A: 12 mg LY3502970 Capsule QD | Cohort 2A: LY3502970 Tablet QD (Dose Level 10) | Cohort 2A:LY3502970 Tablet QD (Dose Level 11) | Cohort 2A: LY3502970 Tablet QD (Dose Level 12) | Cohort 2A: 24 mg LY3502970 Capsule QD | Cohort 2A: LY3502970 Tablet QD (Dose Level 13) | Cohort 2A: LY3502970 Tablet QD (Dose Level 14) | Cohort 2A: LY3502970 Tablet QD (Dose Level 15) | Cohort 2A: 36 mg LY3502970 Capsule QD | Cohort 2A: LY3502970 Tablet QD (Dose Level 16) | Cohort 2A:LY3502970 Tablet QD (Dose Level 17) | Cohort 2A: LY3502970 Tablet QD (Dose Level 18) | Cohort 1B: 1 mg LY3502970 Capsule QD | Cohort 1B: 0.8 mg LY3502970 Tablet QD | Cohort 1B: 3 mg LY3502970 Capsule QD | Cohort 1B: 2.5 mg LY3502970 Tablet QD | Cohort 1B: 6 mg LY3502970 Capsule QD | Cohort 1B:5.5 mg LY3502970 Tablet QD | Cohort 2B:1/3/6 mg LY3502970 Capsule QD (Home Dosing) | Cohort 2B:12 mg LY3502970 Capsule QD | Cohort 2B:9 mg LY3502970 Tablet QD | Cohort 2B:24 mg LY3502970 Capsule QD | Cohort 2B:14.5 mg LY3502970 Tablet QD | Cohort 2B: 36 mg LY3502970 Capsule QD | Cohort 2B: 17.2 mg LY3502970 Tablet QD |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HypersensitivityImmune system disorders | 0/52 | 0/52 | 0/52 | 0/52 | 0/47 | 0/51 | 0/48 | 0/51 | 0/46 | 0/46 | 0/47 | 0/46 | 0/52 | 0/50 | 0/50 | 0/50 | 0/50 | 0/50 | 1/49 | 0/49 | 0/50 | 0/45 | 0/45 | 0/45 | 0/45 | 0/215 | 0/213 | 0/210 | 0/210 | 0/203 | 0/203 | 0/213 | 0/186 | 0/186 | 0/181 | 0/180 | 0/176 | 0/176 |
| Atrial fibrillationCardiac disorders | 0/52 | 0/52 | 0/52 | 0/52 | 0/47 | 0/51 | 0/48 | 0/51 | 0/46 | 0/46 | 0/47 | 0/46 | 0/52 | 0/50 | 0/50 | 0/50 | 0/50 | 0/50 | 0/49 | 0/49 | 0/50 | 0/45 | 0/45 | 0/45 | 0/45 | 0/215 | 0/213 | 0/210 | 0/210 | 0/203 | 0/203 | 0/213 | 0/186 | 0/186 | 0/181 | 0/180 | 1/176 | 0/176 |
| Cholecystitis acuteHepatobiliary disorders | 0/52 | 0/52 | 0/52 | 0/52 | 0/47 | 0/51 | 0/48 | 0/51 | 0/46 | 0/46 | 0/47 | 0/46 | 0/52 | 0/50 | 0/50 | 0/50 | 0/50 | 0/50 | 0/49 | 0/49 | 0/50 | 0/45 | 0/45 | 0/45 | 0/45 | 0/215 | 0/213 | 0/210 | 0/210 | 1/203 | 0/203 | 0/213 | 0/186 | 0/186 | 0/181 | 0/180 | 0/176 | 0/176 |
| Oesophageal carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/52 | 0/52 | 0/52 | 0/52 | 0/47 | 0/51 | 0/48 | 0/51 | 0/46 | 0/46 | 0/47 | 0/46 | 0/52 | 0/50 | 0/50 | 0/50 | 0/50 | 0/50 | 0/49 | 0/49 | 0/50 | 0/45 | 0/45 | 0/45 | 0/45 | 0/215 | 0/213 | 0/210 | 0/210 | 0/203 | 1/203 | 0/213 | 0/186 | 0/186 | 0/181 | 0/180 | 0/176 | 0/176 |
| Event | Cohort 1A: 1 mg LY3502970 Capsule QD | Cohort 1A: LY3502970 Tablet QD (Dose Level 1) | Cohort 1A: LY3502970 Tablet QD (Dose Level 2) | Cohort 1A: LY3502970 Tablet QD (Dose Level 3) | Cohort 1A: 3 mg LY3502970 Capsule QD | Cohort 1A: LY3502970 Tablet QD (Dose Level 4) | Cohort 1A: LY3502970 Tablet QD (Dose Level 5) | Cohort 1A: LY3502970 Tablet QD (Dose Level 6) | Cohort 1A: 6 mg LY3502970 Capsule QD | Cohort 1A: LY3502970 Tablet QD (Dose Level 7) | Cohort 1A: LY3502970 Tablet QD (Dose Level 8) | Cohort 1A: LY3502970 Tablet QD (Dose Level 9) | Cohort 2A: 1/3/6 mg LY3502970 Capsule QD (Home Dosing) | Cohort 2A: 12 mg LY3502970 Capsule QD | Cohort 2A: LY3502970 Tablet QD (Dose Level 10) | Cohort 2A:LY3502970 Tablet QD (Dose Level 11) | Cohort 2A: LY3502970 Tablet QD (Dose Level 12) | Cohort 2A: 24 mg LY3502970 Capsule QD | Cohort 2A: LY3502970 Tablet QD (Dose Level 13) | Cohort 2A: LY3502970 Tablet QD (Dose Level 14) | Cohort 2A: LY3502970 Tablet QD (Dose Level 15) | Cohort 2A: 36 mg LY3502970 Capsule QD | Cohort 2A: LY3502970 Tablet QD (Dose Level 16) | Cohort 2A:LY3502970 Tablet QD (Dose Level 17) | Cohort 2A: LY3502970 Tablet QD (Dose Level 18) | Cohort 1B: 1 mg LY3502970 Capsule QD | Cohort 1B: 0.8 mg LY3502970 Tablet QD | Cohort 1B: 3 mg LY3502970 Capsule QD | Cohort 1B: 2.5 mg LY3502970 Tablet QD | Cohort 1B: 6 mg LY3502970 Capsule QD | Cohort 1B:5.5 mg LY3502970 Tablet QD | Cohort 2B:1/3/6 mg LY3502970 Capsule QD (Home Dosing) | Cohort 2B:12 mg LY3502970 Capsule QD | Cohort 2B:9 mg LY3502970 Tablet QD | Cohort 2B:24 mg LY3502970 Capsule QD | Cohort 2B:14.5 mg LY3502970 Tablet QD | Cohort 2B: 36 mg LY3502970 Capsule QD | Cohort 2B: 17.2 mg LY3502970 Tablet QD |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ConstipationGastrointestinal disorders | 4/52 | 5/52 | 1/52 | 7/52 | 0/47 | 3/51 | 1/48 | 2/51 | 1/46 | 0/46 | 0/47 | 0/46 | 5/52 | 3/50 | 4/50 | 2/50 | 1/50 | 2/50 | 4/49 | 0/49 | 2/50 | 2/45 | 2/45 | 1/45 | 3/45 | 58/215 | 19/213 | 20/210 | 13/210 | 15/203 | 10/203 | 39/213 | 39/186 | 17/186 | 19/181 | 6/180 | 8/176 | 5/176 |
| NauseaGastrointestinal disorders | 1/52 | 0/52 | 1/52 | 1/52 | 2/47 | 4/51 | 4/48 | 2/51 | 0/46 | 3/46 | 2/47 | 5/46 | 7/52 | 3/50 | 3/50 | 1/50 | 4/50 | 2/50 | 2/49 | 2/49 | 4/50 | 1/45 | 0/45 | 6/45 | 2/45 | 13/215 | 7/213 | 29/210 | 13/210 | 19/203 | 17/203 | 44/213 | 32/186 | 12/186 | 31/181 | 15/180 | 9/176 | 6/176 |
| Decreased appetiteMetabolism and nutrition disorders | 1/52 | 0/52 | 0/52 | 0/52 | 1/47 | 0/51 | 0/48 | 0/51 | 0/46 | 0/46 | 0/47 | 0/46 | 1/52 | 0/50 | 1/50 | 0/50 | 0/50 | 0/50 | 0/49 | 0/49 | 1/50 | 1/45 | 0/45 | 0/45 | 0/45 | 8/215 | 4/213 | 15/210 | 3/210 | 3/203 | 1/203 | 43/213 | 1/186 | 5/186 | 4/181 | 5/180 | 1/176 | 2/176 |
| HeadacheNervous system disorders | 1/52 | 1/52 | 1/52 | 0/52 | 1/47 | 2/51 | 3/48 | 2/51 | 4/46 | 2/46 | 2/47 | 3/46 | 5/52 | 2/50 | 3/50 | 2/50 | 3/50 | 5/50 | 1/49 | 3/49 | 2/50 | 3/45 | 2/45 | 3/45 | 1/45 | 34/215 | 19/213 | 37/210 | 17/210 | 25/203 | 17/203 | 23/213 | 36/186 | 18/186 | 18/181 | 15/180 | 28/176 | 6/176 |
| DiarrhoeaGastrointestinal disorders | 0/52 | 1/52 | 2/52 | 0/52 | 1/47 | 3/51 | 2/48 | 3/51 | 0/46 | 0/46 | 0/47 | 2/46 | 1/52 | 1/50 | 3/50 | 2/50 | 2/50 | 0/50 | 2/49 | 2/49 | 2/50 | 1/45 | 1/45 | 2/45 | 3/45 | 3/215 | 2/213 | 7/210 | 3/210 | 3/203 | 3/203 | 19/213 | 19/186 | 5/186 | 23/181 | 12/180 | 11/176 | 4/176 |
| DizzinessNervous system disorders | 0/52 | 0/52 | 0/52 | 1/52 | 0/47 | 2/51 | 1/48 | 1/51 | 1/46 | 0/46 | 0/47 | 0/46 | 1/52 | 1/50 | 0/50 | 1/50 | 1/50 | 2/50 | 0/49 | 6/49 | 2/50 | 2/45 | 0/45 | 2/45 | 1/45 | 2/215 | 2/213 | 4/210 | 3/210 | 5/203 | 1/203 | 7/213 | 9/186 | 3/186 | 8/181 | 6/180 | 6/176 | 3/176 |
| VomitingGastrointestinal disorders | 0/52 | 0/52 | 0/52 | 1/52 | 1/47 | 4/51 | 1/48 | 2/51 | 2/46 | 1/46 | 2/47 | 2/46 | 4/52 | 1/50 | 2/50 | 1/50 | 0/50 | 3/50 | 2/49 | 2/49 | 1/50 | 1/45 | 2/45 | 2/45 | 1/45 | 4/215 | 4/213 | 16/210 | 7/210 | 15/203 | 10/203 | 24/213 | 22/186 | 15/186 | 17/181 | 9/180 | 19/176 | 10/176 |
| Heart rate increasedInvestigations | 0/52 | 0/52 | 0/52 | 0/52 | 0/47 | 0/51 | 0/48 | 0/51 | 0/46 | 0/46 | 0/47 | 0/46 | 0/52 | 0/50 | 0/50 | 1/50 | 1/50 | 1/50 | 0/49 | 1/49 | 1/50 | 0/45 | 4/45 | 1/45 | 0/45 | 0/215 | 0/213 | 3/210 | 1/210 | 1/203 | 0/203 | 5/213 | 3/186 | 2/186 | 5/181 | 2/180 | 5/176 | 4/176 |
| DyspepsiaGastrointestinal disorders | 0/52 | 0/52 | 1/52 | 1/52 | 1/47 | 3/51 | 3/48 | 1/51 | 2/46 | 2/46 | 3/47 | 1/46 | 1/52 | 0/50 | 3/50 | 3/50 | 1/50 | 0/50 | 2/49 | 1/49 | 0/50 | 0/45 | 0/45 | 0/45 | 0/45 | 8/215 | 10/213 | 12/210 | 12/210 | 16/203 | 9/203 | 16/213 | 14/186 | 9/186 | 13/181 | 7/180 | 8/176 | 5/176 |
| Abdominal distensionGastrointestinal disorders | 0/52 | 0/52 | 0/52 | 1/52 | 0/47 | 0/51 | 0/48 | 0/51 | 1/46 | 0/46 | 0/47 | 3/46 | 2/52 | 0/50 | 0/50 | 0/50 | 0/50 | 0/50 | 0/49 | 0/49 | 0/50 | 0/45 | 0/45 | 0/45 | 0/45 | 1/215 | 2/213 | 1/210 | 2/210 | 6/203 | 1/203 | 13/213 | 6/186 | 3/186 | 9/181 | 6/180 | 2/176 | 0/176 |
All enrolled participants.
| Age, Continuous(Years) | Part A: LY3502970 Oral Administration - Cohort 1A | Part A: LY3502970 Oral Administration - Cohort 2A | Part B: LY3502970 Oral Administration - Cohort 1B | Part B: LY3502970 Oral Administration - Cohort 2B | Total |
|---|---|---|---|---|---|
| Mean | 45.9 ± 10.74 | 42.8 ± 10.28 | 44.7 ± 11.12 | 42.1 ± 10.50 | 45.6 ± 10.83 |
| Sex: Female, Male(Participants) | Part A: LY3502970 Oral Administration - Cohort 1A | Part A: LY3502970 Oral Administration - Cohort 2A | Part B: LY3502970 Oral Administration - Cohort 1B | Part B: LY3502970 Oral Administration - Cohort 2B | Total |
|---|---|---|---|---|---|
| Female | 22 | 17 | 93 | 82 | 214 |
| Male | 30 | 35 | 123 | 131 | 319 |
| Ethnicity (NIH/OMB)(Participants) | Part A: LY3502970 Oral Administration - Cohort 1A | Part A: LY3502970 Oral Administration - Cohort 2A | Part B: LY3502970 Oral Administration - Cohort 1B | Part B: LY3502970 Oral Administration - Cohort 2B | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 11 | 12 | 53 | 66 | 142 |
| Not Hispanic or Latino | 41 | 40 | 163 | 146 | 390 |
| Unknown or Not Reported | 0 | 0 | 0 | 1 | 1 |
| Race (NIH/OMB)(Participants) | Part A: LY3502970 Oral Administration - Cohort 1A | Part A: LY3502970 Oral Administration - Cohort 2A | Part B: LY3502970 Oral Administration - Cohort 1B | Part B: LY3502970 Oral Administration - Cohort 2B | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 5 | 2 | 7 |
| Asian | 1 | 1 | 2 | 5 | 9 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 3 | 3 |
| Black or African American | 22 | 21 | 99 | 81 | 223 |
| White | 27 | 30 | 106 | 121 | 284 |
| More than one race | 2 | 0 | 3 | 0 | 5 |
| Unknown or Not Reported | 0 | 0 | 1 | 1 | 2 |
| Region of Enrollment(Participants) | Part A: LY3502970 Oral Administration - Cohort 1A | Part A: LY3502970 Oral Administration - Cohort 2A | Part B: LY3502970 Oral Administration - Cohort 1B | Part B: LY3502970 Oral Administration - Cohort 2B | Total |
|---|---|---|---|---|---|
| United States | 52 | 52 | 216 | 213 | 533 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jun 2024 to primary completion in Jun 2025, 11 months.
Results were first posted in Jul 2026, 1 year 1 month after primary completion.
Of 334 industry-sponsored phase 1 interventional studies under Obesity, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's 11 months is above that.
Counting every sponsor, half of 439 studies reached it within 11 months; a quarter within 6 and three quarters within 24.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Orforglipron